Patrick Buchanan, MD
Interventional Pain Medicine · Camarillo, CANPI 1275828568
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 59 manufacturers reported payments, led by Painteq LLC at 37.3% of the total. Reporting peaked in 2022 at $56,756 and has fallen 51.6% since, to $27,464 in 2025. Among interventional pain medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,505 payments — averaging $145.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Painteq LLC$82K
- Saluda Medical Americas, Inc.$59K
- Abbott$34K
- MML US, Inc.$9K
- Boston Scientific$6K
- Nevro Corp.$6K
- plus $23K from 53 others
Across 102 payments — averaging $2392.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$227K
- Painteq LLC$10K
- Saluda Medical Americas, Inc.$7K
What the payments were for
- Consulting fees$101,44346%
- Speaking & faculty fees$15,0507%
- Travel & lodging$12,0365%
- Food & beverage$59,66327%
- Education$30,64314%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PAINTEQ$78,370
- Evoke$36,912
- Evoke SCS$18,567
- PROCLAIM$17,105
- ReActiv8$8,734
- Proclaim IPG$4,790
- Intracept$4,093
- IonicRF Generator$2,275
- Proclaim Family of SCS IPGs$1,861
- Senza Spinal Cord Stimulation System$1,621
- Senza$1,179
- HA MINUTEMAN G3-R$1,111
- SPRINT PNS System$995
- INTELLIS ADAPTIVESTIM$904
- Prospera$718
- VANTA ADAPTIVESTIM$712
- PATRIOT SI$499
- Omnia$479
- Axium Sheath Braided DRG$345
- Penta SCS Leads$307
How this compares
$218,836 in reported general payments places this provider in the 95th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 17 | $23,263 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 828 | $18,548 |
| BotoxOnabotulinumtoxina | 14 | $18,424 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 273 | $7,286 |
| Gabapentin | 340 | $6,343 |
| MovantikNaloxegol Oxalate | 15 | $5,943 |
| SymproicNaldemedine Tosylate | 11 | $4,914 |
| Lidocaine | 39 | $3,158 |
| Naloxone Hcl | 62 | $3,155 |
| Pregabalin | 213 | $2,042 |
| Diclofenac Sodium | 60 | $1,839 |
| Celecoxib | 103 | $1,704 |
| Oxycodone Hcl | 101 | $1,346 |
| Cyclobenzaprine Hcl | 124 | $1,117 |
| Morphine Sulfate ErMorphine Sulfate | 44 | $853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Botox | $2,265 | $41,68631 claims |
| Redhill Biopharma Inc.Movantik | $62 | $5,94315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 188 interventional pain medicine providers in California.
Other interventional pain medicine in Camarillo
- Joseph CabaretCamarillo$7K
- Michael Verdolinla Mesa$507K
- Tim LeierRancho Mirage$449K
- Jonathan GrossmanVisalia$404K
- Kasra MaasumiRancho Santa Margarita$388K
- Andrew GermanovichRancho Mirage$333K
- David LeeYorba Linda$257K
- Standiford HelmOrange$254K
- Chau VuSanta Rosa$141K
- Phillip LimBuena Park$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.